Statute Details
- Title: Medicines (Labelling) Regulations
- Act Code: MA1975-RG5
- Type: Subsidiary legislation (sl)
- Authorising Act: Medicines Act (Chapter 176), Section 44
- Regulation status: Current version as at 27 Mar 2026
- Commencement: Not stated in the provided extract (note: the Regulations have undergone amendments, including a key amendment effective 1 Nov 2016)
- Citation: G.N. No. S 255/1986; Revised Edition 2000 (31 Jan 2000)
- Key provisions (from extract): Regulation 3 (Definitions); Regulation 3A (Scope of Regulations); Regulation 4 (Particulars to be shown on label); Regulation 6 (Certain substances to be labelled); Regulation 7 (Products to carry date stamp); Regulation 8 (Exception); Regulation 9 (Labels—dimensions, position, etc.)
- Schedules: First Schedule (substances requiring labelling under Reg. 6); Second Schedule (substances triggering “Use by”/expiry labelling under Reg. 7)
What Is This Legislation About?
The Medicines (Labelling) Regulations are Singapore’s rules on what information must appear on the labels of medicinal products sold or supplied to the public (and, in some cases, supplied through wholesale channels). In practical terms, the Regulations aim to ensure that patients, consumers, and healthcare professionals can identify a medicine correctly, understand key directions for use, and—where relevant—see safety-critical information such as expiry dates and the presence of certain substances.
The Regulations operate alongside the Medicines Act (Chapter 176). They focus specifically on labelling rather than licensing or clinical use. That means the compliance question for manufacturers, wholesalers, pharmacies, and dispensers is: “Does the label contain the required particulars, in the required form, and does it apply to the product category we are dealing with?”
Although the Regulations contain multiple provisions, the core compliance themes are consistent: (1) define key terms (such as “appropriate non-proprietary name” and “dispensed medicinal product”); (2) set out what must be on labels for dispensed products; (3) require additional labelling for certain substances; (4) mandate expiry labelling (“Use by”); and (5) prescribe minimum label size, legibility, and placement so that the information is actually usable by the intended reader.
What Are the Key Provisions?
1. Definitions and interpretive framework (Regulation 3)
Regulation 3 provides definitions that drive how the labelling obligations are applied. For practitioners, the most operational definitions are:
- “Appropriate non-proprietary name”: this is the name used for the medicine when it is not marketed under a proprietary brand. The definition ties the choice of name to specified publications (e.g., European Pharmacopoeia, British Pharmacopoeia, US Pharmacopoeia National Formulary, Pharmaceutical Codex (British), British National Formulary) or, where relevant, to an international non-proprietary name selected by the World Health Organisation.
- “Appropriate quantitative particulars”: the quantity of each active ingredient in each dosage unit (or, where there is no dosage unit, the quantity in the container), expressed in weight/volume/capacity/units of activity or as a percentage by weight or volume.
- “Dispensed medicinal product”: a product supplied to a patient by a doctor or dentist, or dispensed by a pharmacist in premises registered for retail pharmacy business.
- “Expiry date”: defined as the date after which (or month/year after which) the medicine should not be used, or the date before which (or month/year before which) it should be used.
These definitions matter because many label requirements depend on whether the product is a dispensed product and whether the label uses the non-proprietary name and quantitative particulars.
2. Scope and exclusions (Regulation 3A)
Regulation 3A is a critical threshold provision. It states that the Regulations do not apply to:
- Chinese proprietary medicines; and
- any medicinal product (other than a Chinese proprietary medicine) that is clinical research material as defined in the Medicines (Medicinal Products as Clinical Research Materials) Regulations 2016.
For compliance planning, this means that entities dealing with Chinese proprietary medicines or clinical research materials should not assume the labelling requirements in these Regulations apply. Instead, they must check the relevant separate regulatory regime for those categories.
3. Dispensed medicinal products: mandatory label particulars (Regulation 4)
Regulation 4 sets out what must appear on the container of a dispensed medicinal product. The label must show, among other things:
- the name of the person to whom the medicinal product is to be administered;
- the name and address of the medical/dental practice, registered pharmacy, hospital, or other institution where it is supplied/dispensed, plus any other identification number or mark;
- the date on which the medicinal product was dispensed;
- the directions for use of the medicinal product;
- the name of the medicinal product, either the appropriate non-proprietary name or the proprietary designation; and
- where the appropriate non-proprietary name is labelled, the appropriate quantitative particulars of the active ingredients.
From a practitioner’s perspective, Regulation 4 is the “patient safety” core: it ensures traceability to the dispensing institution and provides the patient-specific and usage information necessary to reduce medication errors.
4. Labelling for certain substances (Regulation 6) and date stamping (Regulation 7)
The Regulations also impose labelling obligations for products that are not dispensed medicinal products—for example, products sold retail or supplied in circumstances corresponding to retail sale, and products held for such sale/supply.
Regulation 6 applies where a medicinal product for human consumption or use contains any substance specified in the First Schedule. In such cases, every container (and package, where immediately enclosed) must be labelled with a statement in English declaring the presence of that substance. The statement may use a corresponding term specified in the First Schedule or an equivalent term.
Regulation 7 addresses expiry information for medicinal products containing substances specified in the Second Schedule. Subject to Regulation 8, where such a product is sold or supplied (including wholesale dealing), every container and immediate package must be labelled with the words “Use by” (or similar words) followed by the expiry date.
5. Exceptions to expiry labelling (Regulation 8)
Regulation 8 provides targeted carve-outs from the “Use by” requirement in Regulation 7. The exception applies to medicinal products that:
- contain Ascorbic Acid (Vitamin C) or its salts and are sold as confectionery, provided they are not (and are not to be sold with) particulars in writing specifying curative/remedial function, or use for curative/remedial purposes in relation to a disease specified on the container other than coughs, colds or nasal congestion; or
- comprise wholly of substances specified in the Second Schedule and are sold/supplied by way of wholesale dealing for use mainly as an ingredient in preparing another substance or article to be administered for a medicinal purpose.
These exceptions are narrow and fact-sensitive. For wholesalers and manufacturers, the key is whether the product is truly being sold as confectionery without disease claims, or whether it is being supplied as an ingredient for further medicinal preparation.
6. Label form, size, and placement (Regulation 9)
Even where the correct information is included, it must be presented in a way that is readable and conspicuous. Regulation 9 requires that all particulars required by the Regulations be:
- printed in letters not less than 1.5 millimetres in height;
- clearly legible;
- appearing conspicuously in a prominent position; and
- so as to be easily read by an intending purchaser or user under normal conditions of purchase or use.
Regulation 9 also allows reduced-size printing where the container/package is so small that the 1.5mm requirement cannot be met, provided the wording remains clearly legible. It further addresses practical packaging formats: where blister/bubble sealed units are part of a continuous sheet or strip, compliance is deemed if the required particulars are displayed at frequent intervals on the sheet/strip. Similar logic applies where the immediate enclosing package is itself a sealed unit in a continuous series.
Note: The extract provided truncates the remainder of Regulation 9 (“Every package immediately …”). In a full legal review, practitioners should consult the complete text to confirm any additional placement/format rules beyond the excerpt.
How Is This Legislation Structured?
The Regulations are structured as a short set of operative provisions supported by two schedules. The main components are:
- Regulation 1 (Citation) and Regulation 2 (deleted in the 2016 amendment timeline shown).
- Regulation 3 (Definitions) and Regulation 3A (Scope/exclusions).
- Regulation 4 (Particulars to be shown on label for dispensed medicinal products).
- Regulation 6 (Certain substances to be labelled) referencing the First Schedule.
- Regulation 7 (Products to carry date stamp “Use by”) referencing the Second Schedule.
- Regulation 8 (Exception to Regulation 7).
- Regulation 9 (Labels—dimensions, position, legibility, and packaging format rules).
- First Schedule and Second Schedule list the relevant substances that trigger the labelling requirements in Regulations 6 and 7 respectively.
Who Does This Legislation Apply To?
These Regulations apply to parties involved in the sale, supply, possession for sale/supply, and dispensing of medicinal products in Singapore, but the exact obligations depend on product category. In particular, Regulation 4 applies to dispensed medicinal products—typically dispensed by pharmacists or supplied by doctors/dentists to patients.
Regulations 6 and 7 apply to medicinal products other than dispensed medicinal products, including products sold by retail or supplied in circumstances corresponding to retail sale, and products held for such sale/supply. Regulation 7 also expressly covers wholesale dealing for products containing substances in the Second Schedule. However, Regulation 3A excludes Chinese proprietary medicines and clinical research materials from the scope of these Regulations.
Why Is This Legislation Important?
For practitioners, the Medicines (Labelling) Regulations are important because they translate broad medicines regulation into concrete, checkable label requirements. In enforcement and compliance contexts, labelling is often the first point of failure: a product may be otherwise lawful to sell, but still non-compliant if required particulars are missing, inaccurate, not in English where required, or not presented with sufficient prominence and legibility.
The Regulations also support patient safety and traceability. Regulation 4’s patient and dispensing-institution details, dispensing date, and directions for use are directly relevant to medication adherence and reducing dispensing errors. Meanwhile, Regulations 6 and 7 address consumer safety by requiring disclosure of certain substances and mandating expiry (“Use by”) labelling for products containing specified substances.
From a practical perspective, compliance teams should build label-check workflows that map each product to the correct regulatory pathway: dispensed vs non-dispensed; whether the product contains substances listed in the First or Second Schedule; and whether any exceptions in Regulation 8 apply. Because the schedules determine triggering substances, legal review should include confirming the product’s composition against the schedule entries.
Related Legislation
- Medicines Act (Chapter 176) — authorising provision: Section 44
- Medicines (Medicinal Products as Clinical Research Materials) Regulations 2016 — definition cross-reference for clinical research material (Regulation 3A)
- Medicines (Traditional Medicines, Homoeopathic Medicines and other Substances) (Exemption) Order — definition cross-reference for Chinese proprietary medicines (Regulation 3)
Source Documents
This article provides an overview of the Medicines (Labelling) Regulations for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.